Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Byoung Chul Cho

PI/Professor

South Korea

Research Interests

Explore related searches

Professors in South Korea

Articles (21)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2024

Collaborators (16)

Ji-Youn Han

National Cancer Center

SOUTH KOREA

View details

Sanjay Popat

Reader

Institute of Cancer Research

UNITED KINGDOM

View details

Stephen Liu

Associate Professor

Georgetown University School of Medicine

UNITED STATES

View details

Henry Kao

Group Head, Biomarker Sciences

SWITZERLAND

View details

Victor Moreno

Director

Hospital Universitario Fundación Jiménez Díaz

SPAIN

View details

Delvys Rodriguez-Abreu

Universidad de Las Palmas de Gran Canaria

SPAIN

View details

Tae Min Kim

Seoul National University Hospital

SOUTH KOREA

View details

Kyung Hwan Kim

Professor

Yonsei University Health System

SOUTH KOREA

View details

Sang Hoon Lee

Severance Hospital

SOUTH KOREA

View details

Debashis Sarker

King’s College London

UNITED KINGDOM

View details

Darren Wan-Teck Lim

Assoc Prof

SINGAPORE

View details

Elena Garralda

Director

SPAIN

View details

Kristoffer Rohrberg

Ass. Professor

Faculty of Health and Medical Sciences, University of Copenhagen

DENMARK

View details

Adrianus de Langen

The Netherlands Cancer Institute

NETHERLANDS

View details

Javier De Castro

Scientific Director

La Paz University Hospital

SPAIN

View details

Benjamin Solomon

Professor

University of Melbourne

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Byoung Chul Cho

Research Interests

Explore related searches

Articles (21)

A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma

ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non–Small Cell Lung Cancer Treated with First-Line Osimertinib

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC

First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non–Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study

A Phase II Study of Stereotactic Ablative Radiotherapy plus Atezolizumab plus Tiragolumab in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer

MORPHEUS-Lung: biomarkers and clinical response to atezolizumab plus bevacizumab plus stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer

Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD

Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer

Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

Design, synthesis and biological evaluation of symmetric thiadiazole carboxamide derivative as glutaminase inhibitor

Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma

Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis

Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA Study

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study

Real‐world treatment patterns and clinical outcomes in patients with stage <scp>III NSCLC</scp> in Korea: The <scp>KINDLE</scp> study

Collaborators (16)

Ji-Youn Han

Sanjay Popat

Stephen Liu

Henry Kao

Victor Moreno

Delvys Rodriguez-Abreu

Tae Min Kim

Kyung Hwan Kim

Sang Hoon Lee

Debashis Sarker

Darren Wan-Teck Lim

Elena Garralda

Kristoffer Rohrberg

Adrianus de Langen

Javier De Castro

Benjamin Solomon

Make your next move.